Navigating key news stories in pharma

Subscribe

Featured Stories

Featured
Figuring Out the New Economics of Niche
Strategy
Figuring Out the New Economics of Niche
Strategy

As smaller batch products become more prominent within drug development, companies are being required to adopt more agile, modular approaches to ensure commercial viability is achievable.

Read More →
Strategy
News
A Modular Revolution in Biomanufacturing
Expansion
A Modular Revolution in Biomanufacturing
Expansion

SPONSORED CONTENT: As CDMOs face increasing demand for agility and resilience, Azam Razzaq from FUJIFILM Biotechnologies reveals how the expanded Borealis facility is helping to bridge the gap between clinical supply and commercial reality for sponsors.

Read More →
Expansion
Circio and Acuitas Initiate Technology Evaluation Agreement
Dealmaking
Circio and Acuitas Initiate Technology Evaluation Agreement
Dealmaking

The companies have entered into the evaluation agreement to investigate whether circVec circular RNA technology can be delivered to T cells using Acuitas’ targeted lipid nanoparticles.

Read More →
Dealmaking
Figuring Out the New Economics of Niche
Strategy
Figuring Out the New Economics of Niche
Strategy

As smaller batch products become more prominent within drug development, companies are being required to adopt more agile, modular approaches to ensure commercial viability is achievable.

Read More →
Strategy

R&D

Featured
AbbVie Targets Obesity Market with Novel Drug
AbbVie Targets Obesity Market with Novel Drug

Phase I trial results for the company’s novel long-acting amylin analog, have demonstrated significant potential for patients to lose up to 9.79% of body weight in 12–13 weeks with no serious adverse events.

NOFLU Consortium Awarded Contract Worth Up to EUR 148 Million
NOFLU Consortium Awarded Contract Worth Up to EUR 148 Million

The funding, which is part of a larger investment commitment from the European Commission, will be used to progress Ethris’ differentiated mRNA vaccine technology as a treatment for pandemic flu.

Preclinical Study Finds Nanotrastuzumab to be Comparable with Herceptin HYLECTA
Preclinical Study Finds Nanotrastuzumab to be Comparable with Herceptin HYLECTA

The nanoparticle suspension formulation was found to mirror the reference product closely in terms of AUC, Cmax, and Tmax across a 21-day Göttingen minipig study performed by Charles River Laboratories.

Novo Nordisk Reveals Headline Phase III Trial Results Evaluating Combination Obesity Treatment
Novo Nordisk Reveals Headline Phase III Trial Results Evaluating Combination Obesity Treatment

The company’s fixed-dose combination treatment demonstrated superior efficacy to its individual components and was shown to be safe and well-tolerated, consisted with other incretin and amylin-based therapies.

Expansion

Featured
A Modular Revolution in Biomanufacturing
A Modular Revolution in Biomanufacturing

SPONSORED CONTENT: As CDMOs face increasing demand for agility and resilience, Azam Razzaq from FUJIFILM Biotechnologies reveals how the expanded Borealis facility is helping to bridge the gap between clinical supply and commercial reality for sponsors.

ten23 health Opens New Office in Tokyo
ten23 health Opens New Office in Tokyo

The expansion of the Swiss CDMO’s activities into the Asia Pacific area marks a significant milestone in its global growth and means it will be able to better serve pharma and biotech companies across the region.

Vetter Advances New U.S. Site and Upgrades Austrian Facility
Vetter Advances New U.S. Site and Upgrades Austrian Facility

In response to the growing demand for in-human trial material, German CDMO Vetter is expanding its clinical manufacturing network with new infrastructure in the U.S. and Austria.

Lonza Launches Media Development Lab to Optimize Media Formulations
Lonza Launches Media Development Lab to Optimize Media Formulations

The new service, which is available at Lonza’s Singapore site, aims to help bioprocessing customers improve scalability, reduce manufacturing risk, and accelerate development timelines.

Dealmaking

Featured
Circio and Acuitas Initiate Technology Evaluation Agreement
Circio and Acuitas Initiate Technology Evaluation Agreement

The companies have entered into the evaluation agreement to investigate whether circVec circular RNA technology can be delivered to T cells using Acuitas’ targeted lipid nanoparticles.

Partnership Forms for the Development of Inhaled Antiviral Treatments
Partnership Forms for the Development of Inhaled Antiviral Treatments

Aptar Pharma has entered into a technical collaboration with COVIRIX Medical to evaluate its handheld dry powder inhaler device with broad‑spectrum antiviral compounds for high‑risk respiratory viruses.

Alliance Forms to Automate Cell and Gene Therapy Manufacturing
Alliance Forms to Automate Cell and Gene Therapy Manufacturing

San Diego-based Trenchant BioSystems has partnered with engineering firm Invetech to develop a fully automated manufacturing platform it claims could cut production costs by up to 80%.

Lifecore and Indomo Sign New Deal to Develop Drug–Device Combination Acne Treatment
Lifecore and Indomo Sign New Deal to Develop Drug–Device Combination Acne Treatment

Under this new arrangement, the companies will work together to further develop Indomo’s DT-001 candidate, which will be combined with the ClearPen device to allow self-treatment of inflammatory acne lesions.

Strategy

Featured
Figuring Out the New Economics of Niche
Figuring Out the New Economics of Niche

As smaller batch products become more prominent within drug development, companies are being required to adopt more agile, modular approaches to ensure commercial viability is achievable.

INTERPHEX 2026: The Multimodal Future of Sterile Manufacturing
INTERPHEX 2026: The Multimodal Future of Sterile Manufacturing

Automation and living contamination control strategies are helping to answer some of industry’s most pressing sterile manufacturing challenges, explains Dr. Laura Moody from Syntegon.

INTERPHEX 2026: Embedding Intelligence into Bioprocessing
INTERPHEX 2026: Embedding Intelligence into Bioprocessing

Customized engineering and embedded sensors are helping to turn passive single-use assemblies into intelligent, data-rich assets, reveals Rich Jones from Phillips Medisize.

INTERPHEX 2026: Managing Data Integrity in a Multimodal Pipeline
INTERPHEX 2026: Managing Data Integrity in a Multimodal Pipeline

Automated and single-use technologies are offering companies the transparency and agility needed for the newer, more complex drugs in the pipeline, explains Mike D’Avanzo from Alcami.

Future Biopharma

Featured
Tipping the Scales: The Benefits of Continuous Bioprocessing
Tipping the Scales: The Benefits of Continuous Bioprocessing

As cost pressures for drug developers persist, there is an inevitability that the industry will transition to continuous processes to overcome the limitations of traditional batch fed manufacturing.

A New Era for Excipients: Key Takeaways from the IPEC Europe Excipients Forum 2026
A New Era for Excipients: Key Takeaways from the IPEC Europe Excipients Forum 2026

Driven by regulatory evolution and a commitment to sustainability, the excipients’ sector is reinforcing its position as a sophisticated and credible stakeholder in the modern pharmaceutical supply chain.

Opening the Door: The Technology Scaling the Next Era of Emerging Therapies
Opening the Door: The Technology Scaling the Next Era of Emerging Therapies

As emerging therapies target increasingly niche genetic pathways, the adoption of AI modeling, organoids, and advanced AAV delivery is becoming essential to ensure successful clinical progression and patient access.

Transforming the Treatment Landscape with Tailored Therapies
Transforming the Treatment Landscape with Tailored Therapies

Patient outcomes are transforming, thanks to innovative, curative, tailored therapies; however, industry needs to address a few pressing issues to ensure the huge promise of these drugs can be achieved.

Regulatory

Featured
First Targeted CSU Therapy for Children Gets Nod from European Commission
First Targeted CSU Therapy for Children Gets Nod from European Commission

The European Commission has approved dupilumab (Dupixent) as the first targeted therapy for chronic spontaneous urticaria (CSU) in children in the EU, broadening its use in type‑2‑driven inflammatory diseases.

Roche's pMN Therapy Meets Primary Endpoint in Phase III Trial
Roche's pMN Therapy Meets Primary Endpoint in Phase III Trial

The company has revealed that its humanized, glycoengineered Type II anti-CD20 mAb has achieved superior complete remission rates versus tacrolimus in the MAJESTY study.

Rilzabrutinib Gains Regulatory Nods in the U.S. and Japan
Rilzabrutinib Gains Regulatory Nods in the U.S. and Japan

The U.S. FDA has granted breakthrough therapy designation and Japan’s MHLW has designated orphan drug status to Sanofi’s BTK inhibitor, rilzabrutinib (Wayrilz), as a treatment for wAIHA.

CBER Issues RTF for Moderna’s Investigational Flu Shot
CBER Issues RTF for Moderna’s Investigational Flu Shot

According to Moderna, the reasoning for the refusal to review the BLA by the regulatory authority is inconsistent with previous feedback, leading the company to request a Type A meeting.

Upcoming Events

Featured
Bioassays 2026

Bioassays: Scientific Approaches & Regulatory Strategies is a leading bioassay symposium that presents a unique opportunity for attendees to interact with key industry thought leaders and discuss topics such as current perspectives, strategies, and technologies used for bioassays.

PFS & Injectable Drug Devices East Coast 2026

13th Annual Pre-Filled Syringes and Injectable Drug Devices East Coast Conference will return to Boston in April 2026, continuing as a premier event for the latest innovations in injectable drug delivery.

Cell and Gene Meeting on the Med 2026

The Cell & Gene Meeting on the Mediterranean is the leading conference bringing together the ATMP community from Europe and beyond.